Early research (Phase 1)WithdrawnNCT03110588What this trial is testingPhase I Trial of PACE for Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer University of Alabama at Birmingham
Early research (Phase 1)Study completedNCT04628988What this trial is testingCC-90011 and Comparators in Participants With Prostate CancerWho this might be right forProstatic Neoplasms Celgene 6
Testing effectiveness (Phase 2)Looking for participantsNCT07181161What this trial is testingStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer AstraZeneca 283
Testing effectiveness (Phase 2)Looking for participantsNCT06970119What this trial is testingA Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate CancerWho this might be right forProstate Cancer Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Early research (Phase 1)Looking for participantsNCT05613894What this trial is testingDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer University of Utah 33
Not applicableLooking for participantsNCT06600802What this trial is testingIntrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerWho this might be right forCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA) Centre Jean Perrin 120
Testing effectiveness (Phase 2)Looking for participantsNCT06457919What this trial is testingTinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerWho this might be right forProstate Cancer Memorial Sloan Kettering Cancer Center 50
Early research (Phase 1)Looking for participantsNCT06943495What this trial is testingPersonalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)Who this might be right forMetastatic Castrate Resistant Prostate Cancer (mCRPC) Jean-Mathieu Beauregard 60
Post-approval studies (Phase 4)Study completedNCT01977651What this trial is testingEvaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideWho this might be right forMetastatic Castration-resistant Prostate Cancer (mCRPC) Astellas Pharma Global Development, Inc. 424
Post-approval studies (Phase 4)Study completedNCT03641560What this trial is testingA Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based ChemotherapyWho this might be right forMetastatic Castration Resistant Prostate Cancer Astellas Pharma Inc 52
Early research (Phase 1)Study completedNCT04397276What this trial is testingJNJ-70218902 in Participants With Advanced Stage Solid TumorsWho this might be right forNeoplasms Janssen Research & Development, LLC 82
Large-scale testing (Phase 3)Looking for participantsNCT06470243What this trial is testingTesting Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyWho this might be right forCastration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8 SWOG Cancer Research Network 528
Not applicableAvailableNCT05650476What this trial is testingPre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Who this might be right forMetastatic Castration-Resistant Prostate Cancer Pfizer
Early research (Phase 1)Study completedNCT03276572What this trial is testingPhase I Trial of 225Ac-J591 in Patients With mCRPCWho this might be right forProstate Cancer Weill Medical College of Cornell University 32
Post-approval studies (Phase 4)Looking for participantsNCT06099093What this trial is testingPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanWho this might be right forProstate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma Brigham and Women's Hospital 30
Early research (Phase 1)Study completedNCT03822871What this trial is testingA Trial of CTT1403 for Metastatic Castration Resistant Prostate CancerWho this might be right forProstate Cancer Cancer Targeted Technology 17
Not applicableUnknownNCT02362620What this trial is testingPROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.Who this might be right forAdvanced Prostate CancerCabazitaxelDocetaxel Centro Nacional de Investigaciones Oncologicas CARLOS III 402
Not applicableStudy completedNCT06809426What this trial is testingEvaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate CancerWho this might be right forPSMA PET-Positive Castration-Resistant Prostate Cancer Affiliated Hospital of Jiangnan University 13
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07104643What this trial is testingStudy of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）Who this might be right formCRPC TYK Medicines, Inc 48
Not applicableStudy completedNCT03328364What this trial is testingA Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in SwedenWho this might be right forMetastatic Castration Resistant Prostate Cancer Astellas Pharma a/s 211